Pfizer’s Ervogastat + Clesacostat Receives the US FDA’s Fast Track Designation for the Treatment of Non-Alcoholic Steatohepatitis
Shots:
- The US FDA has granted FTD to Ervogastat (diacylglycerol O-acyltransferase 2 inhibitor) + Clesacostat (acetyl-CoA carboxylase inhibitor) for the treatment of NASH with liver fibrosis
- The designation was based on the results from the nonclinical studies and a P-IIa clinical study to evaluate ervogastat + clesacostat which showed that the combination therapy can reduce liver fat with a favorable safety and tolerability profile. The data were published in Nature Medicine
- The combination therapy is currently being evaluated in an ongoing P-II clinical trial to evaluate the impact of treatment on the resolution of NASH or improvement in liver fibrosis. The study is expected to complete in 2024
Ref: Pfizer | Image: Pfizer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
